| Biomarker ID | 985 |
| PMID | 22977195 |
| Year | 2012 |
| Biomarker | PTEN |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Overexpressed for Progression Free Survival |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Immune system, Disease, T cell receptor regulation of apoptosis, Adaptive immune system, TGF-beta regulation of extracellular matrix |
| Experiment | Progression Free Survival |
| Type of Biomarker | Prognostic |
| Cohort | Patients with mCRPC progressing during or within 90 days after at least 12 weeks of docetaxel were included in this phase II trial. 28 patients were avaliable for PCR (molecular) analysis. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p= 0.0003 |
| Method Used | PCR |
| Clinical | Yes |
| Remarks | PFS was defined as the absence of disease progression for biochemical PSA progression |
| Clinical Trial Number | NCT00728663 |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |